Key Points
- CEO sold shares: Oruka CEO Lawrence Otto Klein sold 1,729 shares on March 16 at an average price of $41.30 for $71,407.70, trimming his stake by 0.19% to 927,309 shares (≈$38.3M); several other executives also sold the same day.
- Analyst bullishness: Multiple brokerages have reiterated or raised ratings and targets this week (Leerink raised its target to $86), and the consensus price target is about $59.60, supporting a generally positive analyst outlook.
- Stock and results snapshot: ORKA trades around $41.31 (near a 12‑month high of $42.41) with a $2.05B market cap, and the company recently beat quarterly EPS estimates (loss of $0.45 vs. $0.61 expected).
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 395 shares of the business's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $16,313.50. Following the transaction, the senior vice president owned 18,863 shares of the company's stock, valued at $779,041.90. This represents a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Oruka Therapeutics Price Performance
Shares of NASDAQ ORKA opened at $41.31 on Wednesday. The firm has a market capitalization of $2.05 billion, a PE ratio of -22.21 and a beta of -0.38. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $42.41. The business's fifty day moving average price is $33.51 and its two-hundred day moving average price is $28.05.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16. Equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oruka Therapeutics
Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in shares of Oruka Therapeutics in the 1st quarter worth $2,505,000. Geode Capital Management LLC boosted its stake in Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company's stock valued at $7,932,000 after buying an additional 354,821 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in Oruka Therapeutics during the second quarter worth about $68,000. Intech Investment Management LLC bought a new stake in Oruka Therapeutics in the second quarter worth about $168,000. Finally, JPMorgan Chase & Co. raised its position in Oruka Therapeutics by 567.7% in the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company's stock worth $173,000 after acquiring an additional 13,115 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Oruka Therapeutics
Here are the key news stories impacting Oruka Therapeutics this week:
- Positive Sentiment: Leerink Partners raised its price target from $58 to $86 and kept an "outperform" rating — a very bullish re-rate that signals substantial upside from current levels. Leerink Raises PT to $86
- Positive Sentiment: Multiple firms reiterated or raised ratings/targets this week (BTIG reiterated Buy; Wedbush reiterated Outperform; Guggenheim reiterated Buy; another outlet raised a $50 target), reinforcing analyst conviction and likely driving buying interest. BTIG Reiterates Buy Wedbush Outperform Guggenheim Buy PT Raised to $50
- Neutral Sentiment: Zacks notes the average of Wall Street price targets implies roughly ~41.5% upside — a helpful summary of consensus upside but one that Zacks cautions is an imperfect predictor on its own. Zacks Analyst PT Note
- Negative Sentiment: Several insiders sold shares on March 16: Joana Goncalves sold 7,641 shares (avg $40.91) — filing: Goncalves Form 4; SVP Arjun Agarwal sold 395 shares (avg $41.30) — filing: Agarwal Form 4; CEO Lawrence Klein sold 1,729 shares (avg $41.30) — filing: Klein Form 4. Multiple same-day executive sales can create short-term selling pressure or investor uncertainty even if motives include diversification.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on ORKA shares. Wedbush reiterated an "outperform" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. Stifel Nicolaus lifted their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the company a "buy" rating in a research note on Friday, March 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Barclays raised their price target on Oruka Therapeutics from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Friday, March 13th. Finally, Piper Sandler assumed coverage on shares of Oruka Therapeutics in a report on Thursday, December 18th. They issued an "overweight" rating and a $75.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $59.60.
Check Out Our Latest Report on Oruka Therapeutics
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
